CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP), a biopharmaceutical company focused on developing therapeutics targeting Toll-like Receptors (TLR), announced today the appointment of Louis J. Arcudi III, as Chief Financial Officer. Over the past 10 years, Mr. Arcudi has served in various finance and administration capacities at Peptimmune, Inc., Genzyme Molecular Oncology Corporation and Genzyme Corporation. Mr. Arcudi will join the Company on December 3, 2007.
